SLC16A1 and ovarian cancer: A study of Curtarello M. et al. in ovary cancer, showed that Beva treatment increase MCT4 expression in most oxidative cells, without effect on glycolytic ones, and increased MCT1 expression, both in tumor and liver metastasis, only after Beva long term treatment [36].